Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

This study tests whether using a lower dose of pembrolizumab (an immunotherapy drug) combined with standard chemotherapy (cisplatin and paclitaxel) is an effective and safe first-line treatment for women with advanced cervical cancer that expresses a protein called PD-L1. **You may be eligible if...** - You are a woman aged 18 or older - You have persistent, recurrent, or metastatic cervical cancer (squamous cell, adenocarcinoma, or adenosquamous type) - Your tumor tests positive for PD-L1 (CPS ≥ 1) - You have not received prior chemotherapy for metastatic disease - You cannot have curative surgery or radiation - You have measurable tumors on scans and are in good health (ECOG 0–1) **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your tumor does not express PD-L1 (CPS < 1) - You have had prior chemotherapy for metastatic cervical cancer - Your blood counts or organ function are outside acceptable ranges Talk to your doctor to see if this trial is right for you.